The ancient wisdom of Hippocrates who believed that ‘all disease begins in the gut’ is being validated by modern science, with poor gastrointestinal (GIT) health linked to an increasing number of diseases.
Recent research explored whether there is a relationship between proton pump inhibitor (PPI) use in irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).
With the emergence of antibiotic resistance, one goal of research scientists has been to understand through which medium bacteria communicate, and how we may inhibit this conversation.
Saccharomyces boulardii is a well-researched immunobiotic, which has been shown to restore intestinal integrity and potentially reduce pathogenic gut microbiota.
It is estimated that the global prevalence of IBS is 11%. The most common cause of IBS is small intestinal bacterial overgrowth (SIBO) — in fact, a whopping 60-80% of IBS is due to this common condition, totalling a possible 500 million people worldwide.
Abdominal pain is one of the most common diagnoses in hospitalised children and the leading symptom in child and adolescent GIT diseases. It is also a common symptom of SIBO.
Sarcopenia refers to the age-related loss of muscle mass, strength and functionality. It’s a major factor predisposing older people to falls and fracture.
ACE Inhibitors are a commonly prescribed medication for lowering blood pressure. But developing a cough is a common side-effect for up to 35% of people taking this medication.